BSX - Boston Scientific Corporation
NYSE
->
Healthcare
->
Medical Devices
Marlborough,
United States
Type: Equity
BSX price evolution
BSX
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2913 | $2329 | $865 | $952 |
| Short term investments | ||||
| Net receivables | $2400 | $2304 | $2228 | $2101 |
| Inventory | $2608 | $2561 | $2484 | $2404 |
| Total current assets | $8991 | $8185 | $6514 | $6504 |
| Long term investments | ||||
| Property, plant & equipment | $2951 | $2897 | $2859 | $2635 |
| Goodwill & intangible assets | $19814 | $20200 | $20390 | $19457 |
| Total noncurrent assets | $28117 | $28484 | $28622 | $27539 |
| Total investments | ||||
| Total assets | $37108 | $36669 | $35136 | $34043 |
| Current liabilities | ||||
| Accounts payable | $906 | $921 | $942 | $929 |
| Deferred revenue | ||||
| Short long term debt | $1580 | $1085 | $531 | $513 |
| Total current liabilities | $5576 | $4916 | $4933 | $4579 |
| Long term debt | $8991 | $9534 | $8571 | $8386 |
| Total noncurrent liabilities | $10923 | $11585 | $10673 | $10335 |
| Total debt | $10571 | $10619 | $9102 | $8899 |
| Total liabilities | $16499 | $16501 | $15606 | $14914 |
| Shareholders' equity | ||||
| Retained earnings | $1639 | $1314 | $819 | $315 |
| Other shareholder equity | $164 | $132 | $49 | $231 |
| Total shareholder equity | $20371 | $19926 | $19282 | $18886 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $865 | $928 | $1925 | $1734 |
| Short term investments | ||||
| Net receivables | $2228 | $1970 | $1778 | $1531 |
| Inventory | $2484 | $1867 | $1610 | $1351 |
| Total current assets | $6514 | $5760 | $6317 | $6694 |
| Long term investments | ||||
| Property, plant & equipment | $2859 | $2832 | $2252 | $2084 |
| Goodwill & intangible assets | $20390 | $18822 | $18109 | $15868 |
| Total noncurrent assets | $28622 | $26709 | $25912 | $24083 |
| Total investments | ||||
| Total assets | $35136 | $32469 | $32229 | $30777 |
| Current liabilities | ||||
| Accounts payable | $942 | $862 | $794 | $513 |
| Deferred revenue | ||||
| Short long term debt | $531 | $20 | $261 | $13 |
| Total current liabilities | $4933 | $3803 | $4274 | $3681 |
| Long term debt | $8571 | $8915 | $8804 | $9130 |
| Total noncurrent liabilities | $10673 | $11093 | $11333 | $11770 |
| Total debt | $9102 | $8935 | $9065 | $9143 |
| Total liabilities | $15606 | $14896 | $15607 | $15451 |
| Shareholders' equity | ||||
| Retained earnings | $819 | -$750 | -$1392 | -$2378 |
| Other shareholder equity | $49 | $268 | $263 | $207 |
| Total shareholder equity | $19282 | $17573 | $16622 | $15326 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4120 | $3856 | $3725 | $3527 |
| Cost of revenue | $1270 | $1209 | $1101 | |
| Gross Profit | $2850 | $2647 | $2567 | $2426 |
| Operating activities | ||||
| Research & development | $383 | $366 | $356 | |
| Selling, general & administrative | $1446 | $1364 | $1242 | |
| Total operating expenses | $2330 | $1974 | $1964 | $1734 |
| Operating income | $520 | $673 | $692 | |
| Income from continuing operations | ||||
| EBIT | $499 | $678 | $675 | |
| Income tax expense | $98 | $115 | $1 | $105 |
| Interest expense | $77 | $69 | -$65 | $66 |
| Net income | ||||
| Net income | $324 | $494 | $504 | $504 |
| Income (for common shares) | $324 | $495 | $505 | |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $14240 | $12682 | $9913 | |
| Cost of revenue | $3956 | $3465 | ||
| Gross Profit | $9849 | $8726 | $6448 | |
| Operating activities | ||||
| Research & development | $1323 | $1143 | ||
| Selling, general & administrative | $4520 | $3787 | ||
| Total operating expenses | $7490 | $7079 | $6527 | |
| Operating income | $1647 | -$79 | ||
| Income from continuing operations | ||||
| EBIT | $1610 | $281 | ||
| Income tax expense | $393 | $443 | $2 | |
| Interest expense | -$265 | $470 | $361 | |
| Net income | ||||
| Net income | $1570 | $697 | -$82 | |
| Income (for common shares) | $642 | -$115 | ||
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | $324 | $494 | $505 | $504 |
| Operating activities | ||||
| Depreciation | $311 | $304 | $313 | $300 |
| Business acquisitions & disposals | -$121 | -$113 | -$793 | -$16 |
| Stock-based compensation | $66 | $63 | $59 | $59 |
| Total cash flows from operations | $813 | $164 | $957 | $698 |
| Investing activities | ||||
| Capital expenditures | -$151 | -$171 | -$260 | -$182 |
| Investments | ||||
| Total cash flows from investing | -$271 | -$285 | -$1053 | -$197 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $24 | $2 | $15 | $73 |
| Net borrowings | $1616 | -$41 | ||
| Total cash flows from financing | $24 | $1569 | $15 | $16 |
| Effect of exchange rate | -$1 | -$7 | $8 | -$5 |
| Change in cash and equivalents | $565 | $1441 | -$77 | $513 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $1593 | $697 | $1040 | -$82 |
| Operating activities | ||||
| Depreciation | $1196 | $1136 | $1093 | $1123 |
| Business acquisitions & disposals | -$1900 | -$1561 | -$1153 | $12 |
| Stock-based compensation | $233 | $220 | $194 | $170 |
| Total cash flows from operations | $2503 | $1526 | $1870 | $1508 |
| Investing activities | ||||
| Capital expenditures | -$677 | -$506 | -$458 | -$277 |
| Investments | $2 | $56 | $15 | |
| Total cash flows from investing | -$2574 | -$2011 | -$1597 | -$411 |
| Financing activities | ||||
| Dividends paid | -$28 | |||
| Sale and purchase of stock | $126 | $83 | $60 | $492 |
| Net borrowings | -$4 | -$165 | -$999 | |
| Total cash flows from financing | $5 | -$548 | -$95 | $293 |
| Effect of exchange rate | -$2 | |||
| Change in cash and equivalents | -$70 | -$1042 | $173 | $1388 |
News
|
Surmodics (SRDX) Enters Deal to be Acquired by GTCR for $627M
Zacks
31 May 2024
|
|
Veeva Systems (VEEV) Q1 Earnings Beat Estimates, Margins Up
Zacks
31 May 2024
|
|
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio Now
Zacks via Yahoo Finance
30 May 2024
|
|
Stryker (SYK) to Launch Gamma4 Hip Fracture System in Europe
Zacks via Yahoo Finance
30 May 2024
|
|
Reasons to Retain PacBio (PACB) Stock in Your Portfolio
Zacks via Yahoo Finance
29 May 2024
|
|
Artisan Small Cap Fund Exited Axonics (AXNX) on an Acquisition Announcement
Insider Monkey via Yahoo Finance
29 May 2024
|
|
Intuitive Surgical Stock Gains 20% YTD: Here's Why - Boston Scientific (NYSE:BSX), Align Tech...
Benzinga
28 May 2024
|
|
Boston Scientific shares target raised by Argus By Investing.com
Investing.com
28 May 2024
|
|
Intuitive Surgical (ISRG) Stock Gains 20% YTD: Here's Why
Zacks via Yahoo Finance
28 May 2024
|
|
ResMed (RMD) Up 16.3% Since Last Earnings: Will it Continue?
Zacks via Yahoo Finance
27 May 2024
|
Fundamentals
| Market cap | $124.36B |
|---|---|
| Enterprise value | $132.02B |
| Shares outstanding | 1.47B |
| Revenue | $15.23B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $1.83B |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | 68.11 |
|---|---|
| EV/Sales | 8.67 |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 8.17 |
| P/B ratio | 6.15 |
| Book/Share | 13.74 |
| Cash/Share | 1.98 |
| EPS | $1.24 |
|---|---|
| ROA | 5.11% |
| ROE | 9.31% |
| Debt/Equity | 0.81 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.61 |
| Quick ratio | 1.14 |